AffyImmune Therapeutics' Unattributed VC Round

AffyImmune Therapeutics raised a round of funding on September 13, 2018. Investors include ORI Capital.

AffyImmune Therapeutics is a biopharmaceutical company specializing in affinity tuned Chimeric Antigen Receptor ("CAR") T cell therapy in solid tumors. The Company's proprietary technology may signifi…

Articles about AffyImmune Therapeutics' Unattributed VC Round: